JP2004500426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500426A5 JP2004500426A5 JP2001576014A JP2001576014A JP2004500426A5 JP 2004500426 A5 JP2004500426 A5 JP 2004500426A5 JP 2001576014 A JP2001576014 A JP 2001576014A JP 2001576014 A JP2001576014 A JP 2001576014A JP 2004500426 A5 JP2004500426 A5 JP 2004500426A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- pharmaceutical composition
- pharmaceutically acceptable
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SYHVBRQKMHIAJQ-UHFFFAOYSA-N 3-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCC1=CC=CC(O)=C1O SYHVBRQKMHIAJQ-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001438-1 | 2000-04-18 | ||
| SE0001438A SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | New chemical compounds and their use in therapy |
| PCT/SE2001/000840 WO2001078713A1 (en) | 2000-04-18 | 2001-04-17 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500426A JP2004500426A (ja) | 2004-01-08 |
| JP2004500426A5 true JP2004500426A5 (enExample) | 2008-06-19 |
| JP4819280B2 JP4819280B2 (ja) | 2011-11-24 |
Family
ID=20279367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576014A Expired - Fee Related JP4819280B2 (ja) | 2000-04-18 | 2001-04-17 | カテコールアミンのプロドラッグとしてのフェニルエチルアミンおよび縮合環のヴァリアント（ｖａｒｉａｎｔ）、ならびにその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US6683087B2 (enExample) |
| EP (1) | EP1274411B1 (enExample) |
| JP (1) | JP4819280B2 (enExample) |
| CN (2) | CN100383126C (enExample) |
| AT (1) | ATE300290T1 (enExample) |
| AU (2) | AU2001248982B2 (enExample) |
| CA (1) | CA2406044C (enExample) |
| CZ (1) | CZ20023455A3 (enExample) |
| DE (1) | DE60112269T2 (enExample) |
| DK (1) | DK1274411T3 (enExample) |
| ES (1) | ES2244604T3 (enExample) |
| HU (1) | HU229794B1 (enExample) |
| NZ (1) | NZ521860A (enExample) |
| PL (1) | PL204661B1 (enExample) |
| PT (1) | PT1274411E (enExample) |
| SE (1) | SE0001438D0 (enExample) |
| SI (1) | SI1274411T1 (enExample) |
| WO (1) | WO2001078713A1 (enExample) |
| ZA (1) | ZA200207919B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7910623B2 (en) * | 2005-07-22 | 2011-03-22 | Sloan-Kettering Institute For Cancer Research | Synthesis of scabronines and analogues thereof |
| WO2007013965A2 (en) * | 2005-07-22 | 2007-02-01 | Sloan-Kettering Institute For Cancer Research | Synthesis of scabronines and analogues thereof |
| US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PL2481410T3 (pl) | 2007-01-31 | 2017-03-31 | Bial - Portela & Ca., S.A. | Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania |
| US8129530B2 (en) | 2007-08-31 | 2012-03-06 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| CL2009000628A1 (es) | 2008-03-17 | 2010-04-09 | Bial Portela & Companhia S A | Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros. |
| TW201036949A (en) * | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| US9132094B2 (en) | 2009-04-01 | 2015-09-15 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| US8492538B1 (en) * | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
| JP5641494B2 (ja) * | 2009-09-18 | 2014-12-17 | 株式会社Ｒｉｖｅｒｓｏｎ | ポリフェノール誘導体及びそれの産生方法 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT2791134T (pt) | 2011-12-13 | 2019-12-18 | BIAL PORTELA & Cª S A | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972600A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| US12319710B2 (en) | 2019-05-21 | 2025-06-03 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's diseases |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| EP4247793A1 (en) | 2020-11-17 | 2023-09-27 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| WO2023208867A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF |
| US20250282733A1 (en) | 2022-04-25 | 2025-09-11 | Integrative Research Laboratories Sweden Ab | Novel 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and uses thereof |
| CA3249364A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Res Laboratories Sweden Ab | NEW ESTERS OF COMPOUNDS 1, 2, 3, 4, 4A, 5, 6, 7, 8, 9, 10, 10A-DODECAHYDROBENZO [G]QUINOLIN-6-OL AND THEIR USES |
| WO2025078574A1 (en) | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
| WO2025078571A1 (en) | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1179954A (fr) * | 1956-02-11 | 1959-05-29 | Rhone Poulenc Sa | -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation |
| US3991207A (en) * | 1971-03-18 | 1976-11-09 | Pfizer Inc. | Combination therapy for Parkinson's disease |
| GB1593888A (en) * | 1977-12-22 | 1981-07-22 | Wyeth John & Brother Ltd | Hexahydroazepine piperidine and pyrrolidine derivatives |
| DE3062971D1 (en) | 1979-09-14 | 1983-06-09 | Sandoz Ag | Derivatives of tetraline, their preparation and medicaments containing these compounds |
| ZA805648B (en) * | 1979-09-14 | 1982-04-28 | Sandoz Ltd | Tetraline derivatives, their production and pharmaceutical compositions containing them |
| ATE56958T1 (de) * | 1981-10-16 | 1990-10-15 | Sandoz Ag | 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolinderivate mit pharmazeutischer wirkung. |
| AU6072090A (en) * | 1989-07-05 | 1991-02-06 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| DE69231854T2 (de) * | 1991-04-17 | 2001-10-04 | Pharmacia & Upjohn Co., Kalamazoo | Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten |
| DE4114325A1 (de) | 1991-05-02 | 1992-11-05 | Sandoz Ag | Octahydrobenzo(g)chinolin, seine herstellung und verwendung |
| GB2260980A (en) * | 1991-10-31 | 1993-05-05 | Shell Int Research | Preparation of unsaturated cyclic ketones |
| GB9326010D0 (en) * | 1993-12-21 | 1994-02-23 | Sandoz Ltd | Improvements in or relating to organic compounds |
| CA2267315C (en) * | 1997-08-07 | 2008-01-08 | Fujimoto Brothers Co., Ltd. | Ethylamine derivatives |
| WO2000006536A1 (en) * | 1998-07-28 | 2000-02-10 | Warner-Lambert Company | Hexahydro-naphthalenone oximes and hydrazones |
| SV2001000202A (es) | 1999-10-20 | 2001-10-16 | Warner Lambert Co | Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson |
-
2000
- 2000-04-18 SE SE0001438A patent/SE0001438D0/xx unknown
-
2001
- 2001-04-17 EP EP01922208A patent/EP1274411B1/en not_active Expired - Lifetime
- 2001-04-17 NZ NZ521860A patent/NZ521860A/en not_active IP Right Cessation
- 2001-04-17 ES ES01922208T patent/ES2244604T3/es not_active Expired - Lifetime
- 2001-04-17 CA CA002406044A patent/CA2406044C/en not_active Expired - Fee Related
- 2001-04-17 AT AT01922208T patent/ATE300290T1/de active
- 2001-04-17 US US10/258,014 patent/US6683087B2/en not_active Expired - Fee Related
- 2001-04-17 CZ CZ20023455A patent/CZ20023455A3/cs unknown
- 2001-04-17 JP JP2001576014A patent/JP4819280B2/ja not_active Expired - Fee Related
- 2001-04-17 PL PL365113A patent/PL204661B1/pl unknown
- 2001-04-17 AU AU2001248982A patent/AU2001248982B2/en not_active Ceased
- 2001-04-17 DE DE60112269T patent/DE60112269T2/de not_active Expired - Lifetime
- 2001-04-17 CN CNB2005101253198A patent/CN100383126C/zh not_active Expired - Fee Related
- 2001-04-17 DK DK01922208T patent/DK1274411T3/da active
- 2001-04-17 PT PT01922208T patent/PT1274411E/pt unknown
- 2001-04-17 CN CNB018082858A patent/CN1234351C/zh not_active Expired - Fee Related
- 2001-04-17 HU HU0300543A patent/HU229794B1/hu not_active IP Right Cessation
- 2001-04-17 AU AU4898201A patent/AU4898201A/xx active Pending
- 2001-04-17 WO PCT/SE2001/000840 patent/WO2001078713A1/en not_active Ceased
- 2001-04-17 SI SI200130409T patent/SI1274411T1/sl unknown
-
2002
- 2002-10-02 ZA ZA200207919A patent/ZA200207919B/xx unknown
-
2003
- 2003-12-18 US US10/737,782 patent/US6998405B2/en not_active Ceased
-
2007
- 2007-04-25 US US11/790,465 patent/USRE42802E1/en not_active Expired - Fee Related
-
2010
- 2010-11-12 US US12/945,057 patent/USRE43244E1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500426A5 (enExample) | ||
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| SE0104340D0 (sv) | New compounds | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| SE0104334D0 (sv) | Therapeutic agents | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| CN113993860A (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
| CA2359810A1 (en) | Process for the preparation of pure citalopram | |
| JP2009504748A5 (enExample) | ||
| JP2005511698A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| TW200621772A (en) | Compounds which increase apolipoprotein a-1 production and uses thereof in medicine | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| JP2002527414A5 (enExample) | ||
| HUP0301272A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
| JP2004527492A5 (enExample) | ||
| JP2004532828A5 (enExample) | ||
| MA27881A1 (fr) | Derives d'imidazole utilises comme antagonistes du recepteur du glutamate | |
| JP2004533415A5 (enExample) | ||
| JP2005511559A5 (enExample) | ||
| BR0315840A (pt) | Fosfolipìdeos de anel substituìdo anti-protozoários | |
| EA200600866A1 (ru) | Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний | |
| PL1634595T3 (pl) | Pochodne N-fenylobenzamidu jako leki do leczenia COPD |